EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial

Niekbachsh Mohammadnia, Britta E Wesselink, Willem A Bax iD, Stefan M Nidorf iD, Arend Mosterd iD, Aernoud T L Fiolet iD, Aysun Cetinyurek-Yavuz iD, Peter L Thompson, Shrikant I Bangdiwala iD, John W Eikelboom iD, Jan H Cornel iD, Saloua El Messaoudi iD

Journal of the American Heart Association · 20.05.2025 · 14 (10)

DOI: 10.1161/jaha.124.038687 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 20.05.2025. Verfasst von Niekbachsh Mohammadnia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Radboud University Medical Center Nijmegen The Netherlands. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Colchicine, Secondary Prevention. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The LoDoCo2 (Low‐Dose Colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events in patients with chronic coronary syndrome. Current guidelines recommend colchicine use in selected high‐risk patients. The aim of this secondary analysis was to explore the relative and absolute benefits of colchicine according to baseline risk.

Methods

The LoDoCo2 trial randomized 5522 patients to colchicine 0.5 mg or placebo. The primary end point was a composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia‐driven coronary revascularization. First, a LoDoCo2 risk score was developed by Cox regression to identify high‐risk features for the primary end point. Second, the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention was applied to explore robustness of findings.

Results

In the LoDoCo2 risk score, high‐risk features were age ≥75, diabetes, and current smoker. In high‐risk (≥1 high‐risk feature), compared with low‐risk (0 high‐risk features) patients, colchicine was associated with consistent relative (high risk: hazard ratio [HR], 0.72 [95% CI, 0.56–0.94] versus low risk: HR, 0.67 [95% CI, 0.52–0.88]; P for interaction=0.73) and absolute benefits (high risk: HR, −1.33 [95% CI, −2.38 to −0.27] versus low risk: HR, −0.93 [95% CI −1.57 to −0.30] events per 100 person‐years). Using the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention, consistent relative and absolute benefits were found in high‐, intermediate‐, and low‐risk patients.

Conclusions

In patients with chronic coronary syndrome, the relative and absolute benefits of colchicine were consistent in those at high, intermediate, and low risk for cardiovascular events. These findings support the use of colchicine across the spectrum of baseline risk. Registration URL: https://www.anzctr.org.au ; Unique identifier: 12614000093684.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesColchicineSecondary PreventionAgedFemaleHumansMaleMiddle AgedMyocardial InfarctionRisk AssessmentRisk FactorsTreatment OutcomeSecondary Data Analysis

Stichwörter der Autor:innen

chronic coronary syndromecolchicinerisk stratificationsecondary prevention

Substanzen

Colchicine

Autor:innen und Institutionen

  • Department of Cardiology Radboud University Medical Center Nijmegen The Netherlands.
  • Department of Internal Medicine Northwest Clinics Alkmaar Netherlands.
  • Heart and Vascular Research Institute of Western Australia Perth WA Australia.
  • Dutch Network for Cardiovascular Research (WCN) Utrecht The Netherlands.
  • Department of Cardiology Meander Medical Center Amersfoort The Netherlands.
  • Department of Cardiology University Medical Center Utrecht Utrecht The Netherlands.

ORCID-Profile: Willem A Bax, Stefan M Nidorf, Arend Mosterd, Aernoud T L Fiolet, Aysun Cetinyurek-Yavuz, Shrikant I Bangdiwala, John W Eikelboom, Jan H Cornel, Saloua El Messaoudi

Zitieren

APA

Mohammadnia, N., Wesselink, B. E., Bax, W. A., Nidorf, S. M., Mosterd, A., Fiolet, A. T. L., Cetinyurek-Yavuz, A., Thompson, P. L., Bangdiwala, S. I., Eikelboom, J. W., Cornel, J. H., & El Messaoudi, S. (2025). Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial. Journal of the American Heart Association, 14(10). https://doi.org/10.1161/jaha.124.038687

Vancouver

Mohammadnia N, Wesselink BE, Bax WA, Nidorf SM, Mosterd A, Fiolet ATL, et al. Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial. Journal of the American Heart Association. 2025;14(10). doi:10.1161/jaha.124.038687

BibTeX
@article{Mohammadnia2025,
  author = {Mohammadnia, Niekbachsh and Wesselink, Britta E and Bax, Willem A and Nidorf, Stefan M and Mosterd, Arend and Fiolet, Aernoud T L and Cetinyurek-Yavuz, Aysun and Thompson, Peter L and Bangdiwala, Shrikant I and Eikelboom, John W and Cornel, Jan H and El Messaoudi, Saloua},
  title = {Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {10},
  doi = {10.1161/jaha.124.038687}
}
Kostenlos starten →